Drugs / Ticagrelor
Ticagrelor
also known as
AZD6140 · BRILINTA · BRILINTA (ticagrelor) · Brilique · Ticagrelor (Brilinta) · AR-C126532XX · Brilavus · Possia · +2 more
Small molecule targets P2RY12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed acute coronary syndrome 2 milestones | |||||
| Rejected (CRL) | US (FDA) | BRILINTA | acute coronary syndrome | 2010-12-17 | “the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor” astrazeneca.com ↗ |
| Filed | US (FDA) | BRILINTA | acute coronary syndrome | 2009-11-19 | “AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor” astrazeneca.com ↗ |
| Filed stroke disorder 1 milestone | |||||
| Filed | US (FDA) | Brilinta | stroke disorder | 2020-07-09 | “AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA)” astrazeneca.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (6) | US (FDA) | BRILINTA | — | 2015-09-03 – 2024-03-22 | fda.gov ↗ |
| Approved | US (FDA) | BRILINTA | — | 2011-07-20 | fda.gov ↗ |
| Approved | EU (EMA) | Brilique | — | 2010-12-03 | europa.eu ↗ |
Trials 300 · started per year
today
EU approved 2010
US approved 2011
1
2
4
1
3
6
23
29
46
38
18
17
17
15
13
12
7
18
17
4
9
2007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06339021 | Apr 2024 → Dec 2026 expected | ST-elevation myocardial infarction | Shenyang Northern Hospital | Not yet recruiting | No outcome recorded |
| Phase 128 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT07438886 | Mar 2026 → Mar 2027 expected | — | Advenchen Laboratories, LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07444164 | Jan 2025 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT06584812 | Sep → Dec 2024 | acute coronary syndrome, ischemic stroke | Tianjin Institute of Pharmaceutical Research Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06671470 | Aug → Sep 2024 | insomnia | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06554821 | Aug → Oct 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06233266 | Jun → Jul 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04588727 | Oct 2020 → Jan 2022 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03492931 | Mar 2018 → May 2019 | sickle cell disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03430661 | Jan 2018 → May 2019 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03126695 | May → Jul 2017 | sickle cell disease | AstraZeneca | Completed | Met primary |
| Phase 1 | NCT02400333 | Jun → Jul 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03092076 | May → Oct 2015 | — | Guangdong Provincial People's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02080858 | May → Oct 2014 | acute coronary syndrome, atrial fibrillation | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT02022748 | Dec 2013 → May 2016 | chronic renal failure syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01876797 | Jul → Aug 2013 | — | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01887626 | Jul → Sep 2013 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01883869 | Jun 2013 → Jun 2016 | acute lung injury, pneumonia | University of Kentucky | Completed | No outcome recorded |
| Phase 1 | NCT01744288 | Dec 2012 → Apr 2014 | platelet aggregation, spontaneous | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01734772 | Nov 2012 → Jun 2013 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT01595854 | May → Jun 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01588626 | May → Jun 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01504906 | Jan → Jun 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01350921 | May 2011 → Mar 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01226602 | Dec 2010 → Apr 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00721448 | Jun → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00738842 | May → Jul 2008 | coronary artery disorder, gout | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00685906 | Apr → Oct 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00733265 | Feb 2007 → Sep 2008 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05831462 | Jun 2023 → Mar 2024 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04206176 | Oct 2019 → Mar 2020 | platelet disorder, undefined | The University of The West Indies | Completed | No outcome recorded |
| Phase 1/2 | NCT02091921 | Feb 2014 → Nov 2016 | limb ischemia | University of Southern California | Completed | No outcome recorded |
| Phase 222 trials · 1 met primary · 4 missed | ||||||
| Phase 2 | NCT05093790 | Mar → Nov 2022 | coronary artery disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT05149560 | Dec 2021 → Jun 2025 | acute myocardial infarction | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 2 | NCT04766437 | Feb 2021 → Sep 2022 | acute coronary syndrome | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 2 | NCT03928353 | Apr → Oct 2019 | — | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03606642 | Nov 2018 → Dec 2021 | atherosclerosis, coronary artery disorder | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03145194 | Jan 2017 → Nov 2018 | ST-elevation myocardial infarction | Papworth Hospital NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT02677545 | Dec 2016 → Apr 2022 | carotid stenosis | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2 | NCT03487406 | Sep 2015 → Nov 2017 | chronic obstructive pulmonary disease | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT02519608 | Sep 2015 → Jun 2016 | chronic obstructive pulmonary disease, coronary artery disorder | University Hospital of Ferrara | Completed | Met primary |
| Phase 2 | NCT02482298 | Jul 2015 → Nov 2016 | sickle cell disease | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT02319941 | May 2015 → Feb 2017 | acute coronary syndrome | CardioVascular Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02227368 | Oct 2014 → May 2016 | peripheral arterial disease | AstraZeneca | Terminated | Missed primary |
| Phase 2 | NCT02214121 | Sep 2014 → Feb 2017 | platelet aggregation, spontaneous | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT02435563 | Aug 2014 → Apr 2015 | — | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 2 | NCT01998399 | Aug 2014 → Dec 2015 | pneumonia | Gordon Bernard | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT02071212 | Feb 2014 → Jun 2018 | coronary artery disorder | Hellenic Cardiovascular Research Society | Completed | No outcome recorded |
| Phase 2 | NCT01766466 | Jan → Feb 2013 | coronary artery disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 2 | NCT02285751 | Nov 2012 → Jul 2020 | critical illness polyneuropathy | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT01738100 | Sep 2012 → Dec 2016 | ST-elevation myocardial infarction | Hyeon-Cheol Gwon | Unknown | Missed primary |
| Phase 2 | NCT01118325 | Apr 2010 → Mar 2011 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00642811 | May 2008 → Mar 2009 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00528411 | Oct 2007 → Mar 2009 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2/310 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT06653348 | Apr 2024 → Jul 2026 overdue | transient ischemic attack | Mazandaran University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03381742 | Dec 2017 → Dec 2018 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT03062462 | Feb 2017 → Jul 2019 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02889549 | Aug 2016 → Oct 2017 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02506140 | Aug 2015 → Mar 2017 | transient ischemic attack | Beijing Tiantan Hospital | Completed | Met primary |
| Phase 2/3 | NCT02110303 | Mar 2015 → May 2017 | coronary atherosclerosis | University of Edinburgh | Completed | Missed primary |
| Phase 2/3 | NCT02230527 | Oct 2014 → May 2020 | peripheral arterial disease | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02048228 | Oct 2014 → Mar 2016 | — | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02044146 | Sep 2014 → Oct 2016 | acute coronary syndrome | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT01894789 | Mar 2013 → Mar 2015 | coronary artery disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 360 trials · 8 met primary · 9 missed | ||||||
| Phase 3 | NCT07821008 | Sep 2026 → Dec 2029 expected | acquired aneurysmal subarachnoid hemorrhage, brain ischemia | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07582835 | Apr 2026 → Apr 2028 expected | acute coronary syndrome, coronary artery disorder | Cardiocentro Ticino | Recruiting | No outcome recorded |
| Phase 3 | NCT06853535 | May 2025 → Jun 2027 expected | ischemic stroke | Sichuan Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05997693 | Aug 2024 → Jan 2027 expected | coronary artery disorder | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 3 | NCT06316570 | Apr 2024 → Dec 2025 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06318481 | Feb 2024 → Feb 2025 | ST-elevation myocardial infarction | National Institute of Cardiovascular Diseases, Pakistan | Completed | Missed primary |
| Phase 3 | NCT05952206 | Oct 2023 → Jan 2027 expected | coronary artery disorder | iVascular S.L.U. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05903976 | Jun 2023 → Jun 2025 | acute coronary syndrome, coronary artery disorder | Azienda Ospedaliera Universitaria Policlinico "G. Martino" | Unknown | No outcome recorded |
| Phase 3 | NCT05476991 | May 2023 → Sep 2027 expected | atherosclerosis, cerebral infarction, coronary artery disorder, myocardial infarction +1 | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05779059 | Apr 2023 → Dec 2024 | acute coronary syndrome, intermediate coronary syndrome, myocardial infarction | Collegium Medicum w Bydgoszczy | Unknown | No outcome recorded |
| Phase 3 | NCT05047172 | Aug 2022 → Jan 2027 expected | intracranial arteriosclerosis, stroke disorder | University of Florida | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04738097 | Aug 2021 → Oct 2023 | transient ischemic attack | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04946929 | Jul 2021 → Dec 2022 | — | RenJi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04739384 | Apr 2021 → Jun 2022 | ST-elevation myocardial infarction, acute coronary syndrome, coronary artery disorder | Federico II University | Completed | No outcome recorded |
| Phase 3 | NCT04360720 | Oct 2020 → Nov 2024 | acute coronary syndrome | Hospital Israelita Albert Einstein | Completed | No outcome recorded |
| Phase 3 | NCT04293172 | Jun 2020 → Oct 2022 | sickle cell disease | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT04078737 | Sep 2019 → Jun 2021 | transient ischemic attack | Beijing Tiantan Hospital | Completed | Met primary |
| Phase 3 | NCT04069234 | Sep 2019 → Oct 2021 | coronary microvascular disorder, type 2 diabetes mellitus | Region Skane | Withdrawn | No outcome recorded |
| Phase 3 | NCT04007055 | Aug 2019 → Mar 2023 | peripheral arterial disease, peripheral arterial occlusive disease 1 | Marissa Jarosinski | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03822377 | Jun 2019 → Aug 2020 | ST-elevation myocardial infarction | Azienda Ospedaliero Universitaria di Sassari | Completed | No outcome recorded |
| Phase 3 | NCT03789916 | Jan 2019 → Aug 2021 overdue | coronary artery disorder | Campus-Bio-Medico University | Recruiting | No outcome recorded |
| Phase 3 | NCT03649711 | Nov 2018 → Sep 2021 | chronic kidney disease, ischemic stroke, myocardial infarction | University of Arkansas | Completed | Met primary |
| Phase 3 | NCT03331484 | Nov 2018 → Jul 2023 | acute coronary syndrome, atrial fibrillation | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03357874 | Oct 2018 → Jan 2023 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT03615924 | Sep 2018 → Aug 2020 | sickle cell disease | AstraZeneca | Terminated | Missed primary |
| Phase 3 | NCT03354429 | Jan 2018 → Dec 2019 | transient ischemic attack | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT03251859 | Aug 2017 → Feb 2018 | myocardial infarction | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 3 | NCT03078465 | Jun 2017 → May 2021 | coronary artery disorder | Nanjing First Hospital, Nanjing Medical University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02617290 | Jan 2017 → May 2020 | coronary artery disorder, myocardial infarction, myocardial ischemia | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT02944123 | Sep 2016 → Feb 2020 | acute coronary syndrome | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT02817789 | May 2016 → May 2018 | aortic valve stenosis | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02675205 | Dec 2015 → Jul 2020 | brain aneurysm | Fondation Ophtalmologique Adolphe de Rothschild | Completed | No outcome recorded |
| Phase 3 | NCT01739556 | Jun 2015 → Jan 2018 | ST-elevation myocardial infarction | Clinical Centre of Serbia | Terminated | No outcome recorded |
| Phase 3 | NCT02352402 | Mar 2015 → Aug 2020 | acute coronary syndrome, coronary artery disorder | J.M. ten Berg | Unknown | Missed primary |
| Phase 3 | NCT02406911 | Feb → Jun 2015 | chronic kidney disease | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02415803 | Dec 2014 → Dec 2016 | acute coronary syndrome | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT01930591 | May 2014 → Oct 2016 | acute myocardial infarction | Unity Health Toronto | Completed | Met primary |
| Phase 3 | NCT01991795 | Feb 2014 → Jan 2019 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT02086903 | Feb → Apr 2014 | — | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT01994720 | Jan 2014 → Mar 2016 | transient ischemic attack | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT02075125 | Jan 2014 → Apr 2015 | ST-elevation myocardial infarction | Dong-A University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01992523 | Nov 2013 → Mar 2014 | acute coronary syndrome | David Antoniucci | Completed | Met primary |
| Phase 3 | NCT01813435 | Jul 2013 → Nov 2015 | coronary artery disorder | ECRI bv | Completed | Missed primary |
| Phase 3 | NCT01755520 | Apr 2013 → May 2018 | acute coronary syndrome, coronary artery disorder | German Heart Center Munich | Terminated | Missed primary |
| Phase 3 | NCT01805596 | Apr 2013 → Feb 2016 | coronary artery disorder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT01757262 | Jan → Apr 2013 | coronary artery disorder | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT01812330 | Jan 2013 → Dec 2015 | acute coronary syndrome | General Hospital of Chinese Armed Police Forces | Unknown | No outcome recorded |
| Phase 3 | NCT02163954 | Jan → Aug 2013 | chronic kidney disease | Kyunghee University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01732822 | Dec 2012 → Sep 2016 | peripheral arterial disease | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT01660373 | Aug 2012 → Aug 2013 | acute coronary syndrome | Pusan National University Yangsan Hospital | Unknown | Missed primary |
| Phase 3 | NCT01543932 | Jul 2012 → Dec 2013 | coronary artery disorder | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 3 | NCT01626534 | Mar 2012 → Feb 2014 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01511471 | Jan → Feb 2012 | qualitative platelet defect | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01515345 | Jul 2011 → Jan 2013 | coronary artery disorder, platelet aggregation, spontaneous | Kaiser Franz Josef Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01360437 | May → Dec 2011 | acute coronary syndrome, coronary artery disorder | University of Patras | Completed | Met primary |
| Phase 3 | NCT01294462 | Feb 2011 → Jul 2012 | acute coronary syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01225562 | Oct 2010 → Dec 2014 | atherosclerotic cardiovascular disease, cardiac arrest, myocardial infarction, stroke disorder | AstraZeneca | Completed | Mixed |
| Phase 3 | NCT02394145 | Sep 2009 → Aug 2015 | chronic kidney disease | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00391872 | Oct 2006 → Mar 2009 | acute coronary syndrome | AstraZeneca | Completed | Met primary |
| Phase 4145 trials · 16 met primary · 12 missed | ||||||
| Phase 4 | NCT07080684 | Nov 2026 → Dec 2027 expected | coronary artery disorder | University of Messina | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07602257 | Oct 2026 → Dec 2029 expected | — | Ottawa Heart Institute Research Corporation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07507500 | Sep 2026 → Jul 2029 expected | acute myocardial infarction | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Recruiting | No outcome recorded |
| Phase 4 | NCT06588595 | Nov 2024 → Aug 2027 expected | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06613191 | Oct 2024 → Dec 2025 overdue | coronary artery disorder, peripheral vascular disease | Ochsner Health System | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06486363 | Aug 2024 → Jul 2026 overdue | brain aneurysm | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06509893 | Aug 2024 → Dec 2025 overdue | coronary artery disorder | Shiraz University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT06228456 | Apr 2024 → Dec 2026 expected | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06283888 | Apr 2024 → Apr 2028 expected | acute coronary syndrome | Zunyi Medical College | Recruiting | No outcome recorded |
| Phase 4 | NCT05773989 | Jan → Dec 2024 | coronary artery disorder | St. Antonius Hospital | Unknown | No outcome recorded |
| Show all 145 trials opens the full record — a long page | ||||||
| Phase not applicable31 trials · 7 met primary | ||||||
| — | NCT07587099 | May 2026 → Dec 2029 expected | coronary artery disorder | Gan Lijun | Recruiting | No outcome recorded |
| — | NCT05650411 | Apr 2026 → May 2028 expected | coronary stenosis | IGLESIAS Juan Fernando | Recruiting | No outcome recorded |
| — | NCT07432516 | Feb 2026 → Jun 2033 expected | coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06714526 | Oct 2025 → Aug 2027 expected | cerebral atherosclerosis | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| — | NCT07613840 | Apr 2025 → Apr 2027 expected | peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
| — | NCT06015477 | Jan 2024 → Jul 2025 | brain aneurysm | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT06301776 | Dec 2023 → Dec 2025 | precerebral artery stenosis | The Fourth Affiliated Hospital of China Medical University | Unknown | No outcome recorded |
| — | NCT06058130 | Sep 2023 → Oct 2025 | atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05936606 | Aug 2023 → May 2027 expected | coronary artery disorder | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05986968 | Jul 2023 → Dec 2025 overdue | ST-elevation myocardial infarction | Radboud University Medical Center | Recruiting | No outcome recorded |
| — | NCT05825391 | May → Oct 2023 | brain aneurysm | Beijing Tiantan Hospital | Completed | Met primary |
| — | NCT04971356 | Nov 2021 → Mar 2024 overdue | acute coronary syndrome | Xijing Hospital | Active not recruiting | Met primary |
| — | NCT04989257 | Aug 2021 → Jun 2026 | ischemic disease | Yonsei University | Unknown | No outcome recorded |
| — | NCT04948749 | Jul 2021 → Dec 2027 expected | intracranial arteriosclerosis, stroke disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07597239 | Nov 2020 → Feb 2026 overdue | arterial occlusion, peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| — | NCT04338919 | Apr 2020 → Apr 2021 | acute coronary syndrome | Fujian Medical University | Unknown | No outcome recorded |
| — | NCT03577652 | Jul 2017 → Jan 2018 | coronary artery disorder | Shenyang Northern Hospital | Completed | Met primary |
| — | NCT03111420 | Jan 2017 → Jun 2018 | platelet disorder, undefined | Aggredyne, Inc. | Completed | No outcome recorded |
| — | NCT03005704 | Jan → Dec 2017 | aspirin resistance, platelet disorder, undefined | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| — | NCT02798874 | May → Dec 2016 | cardiovascular disorder | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02762864 | May 2016 → Apr 2019 | peripheral arterial disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT02865824 | Jan 2016 → Dec 2018 | polyp of colon | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| — | NCT02612480 | Oct → Dec 2015 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT02531165 | Sep 2015 → Feb 2018 | acute myocardial infarction | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| — | NCT02244710 | Mar 2015 → Sep 2016 | acute coronary syndrome | Fundación Investigación Sanitaria en León | Completed | No outcome recorded |
| — | NCT02618733 | Dec 2014 → Dec 2016 | acute coronary syndrome | Dong-A University | Completed | Met primary |
| — | NCT02079194 | Mar 2014 → Jul 2018 | coronary artery disorder | Samsung Medical Center | Unknown | Met primary |
| — | NCT02016170 | Mar 2014 → Oct 2015 | acute coronary syndrome, coronary artery disorder | University of Florida | Completed | Met primary |
| — | NCT01731041 | Jan 2013 → Jun 2014 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| — | NCT01795820 | Nov 2012 → Jan 2013 | acute coronary syndrome | University Magna Graecia | Completed | No outcome recorded |
| — | NCT01701453 | Aug 2012 → Nov 2017 | acute coronary syndrome | Samsung Medical Center | Unknown | Met primary |
| Comparator or background therapy141 trials | ||||||
| Phase 0 | NCT05278637 Comparator | Nov 2013 → Dec 2016 | aspirin resistance, nuclear ribonucleic acid, platelet aggregation, spontaneous | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT05373277 Comparator | May → Dec 2022 | — | Helsinki University Central Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04091074 Comparator | Jan → Dec 2022 | carotid stenosis | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT05162131 Background | Dec 2021 → Dec 2022 | — | SFJ Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04945616 Background | Jul → Oct 2021 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Show all 141 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 46
| Date | Issuer | Release |
|---|---|---|
| 2025-10-01 | Alembic Pharmaceuticals Ltd. | Regulatory 29th October, 2025 Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 60 mg. |
| 2025-05-01 | Alembic Pharmaceuticals Ltd. | Regulatory Press Release for Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg. |
| 2020-11-06 | AstraZeneca | Regulatory Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stroke or high-risk transient ischaemic attack astrazeneca.com ↗ |
| 2020-07-16 | AstraZeneca | Results Brilinta significantly reduced the rate of the composite of stroke and death in patients who had an acute ischaemic stroke or transient ischaemic attack in the Phase III THALES trial astrazeneca.com ↗
Furthermore, aspirin plus Brilinta significantly reduced the rate of the first secondary endpoint of ischaemic stroke by 21%, compared to aspirin alone up to day 30. |
| 2020-07-09 | AstraZeneca | Regulatory Brilinta granted FDA Priority Review for the reduction of subsequent stroke in patients who had an acute ischemic stroke or transient ischemic attack astrazeneca.com ↗ |
| 2020-06-01 | AstraZeneca | Regulatory Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease astrazeneca.com ↗
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease. |
| 2020-03-30 | AstraZeneca | Results Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial astrazeneca.com ↗
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients. |
| 2020-01-27 | AstraZeneca | Results Brilinta met primary endpoint in Phase III THALES trial in stroke astrazeneca.com ↗
Results of the Phase III THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack. |
| 2019-09-01 | AstraZeneca | Results Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes in Phase III THEMIS trial astrazeneca.com ↗ |
| 2019-08-29 | AstraZeneca | Results AstraZeneca to present data at ESC Congress 2019 that potentially redefine the treatment of heart failure astrazeneca.com ↗
Brilinta THEMIS trial shows potential in treating patients with CAD and T2D before they experience a heart attack or stroke |
| 2019-02-25 | AstraZeneca | Results Brilinta’s Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes astrazeneca.com ↗
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone. |
| 2018-05-17 | AstraZeneca | Results New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma astrazeneca.com ↗
AstraZeneca today announced results from the Phase III SYGMA trials 1 , 2 of Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma. |
| 2018-02-07 | AstraZeneca | Results Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease astrazeneca.com ↗ |
| 2018-01-26 | AstraZeneca | Results AstraZeneca reports top-line Phase III KRONOS trial results for PT010 triple combination therapy in chronic obstructive pulmonary disease astrazeneca.com ↗
In total, eight of the nine primary endpoints in the KRONOS trial were met, including two non-inferiority endpoints to qualify PT009, one of the comparators. |
| 2017-08-24 | AstraZeneca | Results Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack astrazeneca.com ↗
The latest results highlight a potential protective CV benefit associated with longer-term treatment, versus the standard 12-month post-event treatment period, with Brilinta 60mg, and are due to be presented in full at the ESC Congress in Barcelona, Spain. |
| 2016-10-04 | AstraZeneca | Results AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease astrazeneca.com ↗
Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease (PAD) patient population and therefore did not meet the primary endpoint of the trial. |
| 2016-03-23 | AstraZeneca | Results AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke astrazeneca.com ↗
The primary efficacy endpoint of time to first occurrence of any event from the composite of stroke (ischaemic or haemorrhagic), myocardial infarction (MI, also known as heart attack) and death was not met. |
| 2016-02-19 | AstraZeneca | Regulatory Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack astrazeneca.com ↗
AstraZeneca today announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event. |
| 2015-12-18 | AstraZeneca | Regulatory BRILIQUE (ticagrelor) receives positive European Union CHMP opinion for extended treatment of patients with a history of heart attack astrazeneca.com ↗
We are very pleased with today’s positive opinion from the CHMP. |
| 2015-09-03 | AstraZeneca | Regulatory US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack astrazeneca.com ↗
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA ® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year. |
| 2015-08-31 | AstraZeneca | Results PEGASUS-TIMI 54 sub-analysis shows importance of continuing treatment with BRILINTA beyond one year following a heart attack astrazeneca.com ↗
Those patients randomised into the ticagrelor arms of the study within 30 days of withdrawal of therapy experienced a 27% reduction in the risk of developing a subsequent event. |
| 2015-04-29 | AstraZeneca | Regulatory US FDA grants Priority Review for potential new indication for BRILINTA astrazeneca.com ↗
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. |
| 2015-03-14 | AstraZeneca | Results PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack astrazeneca.com ↗
Both 90mg and 60mg study doses of ticagrelor with aspirin significantly reduced the primary composite endpoint of cardiovascular (CV) death, myocardial infarction (MI) or stroke compared to placebo. |
| 2015-01-14 | AstraZeneca | Results PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses astrazeneca.com ↗
Both BRILINTA 60mg and 90mg demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack |
| 2014-09-01 | AstraZeneca | Results New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients astrazeneca.com ↗
AstraZeneca today announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. |
| 2011-12-15 | AstraZeneca | Regulatory G-BA issues positive final medical benefit assessment for BRILIQUE in Germany astrazeneca.com ↗
AstraZeneca today announced that the German assessment body, the Federal Joint Committee (G-BA), has issued its final decision regarding the medical benefit of BRILIQUE (ticagrelor). |
| 2011-10-21 | AstraZeneca | Results AstraZeneca to present new healthcare economics data demonstrating cost-effectiveness of BRILIQUE at ISPOR EU astrazeneca.com ↗
Across each country and measurement, results showed that even at a higher price, BRILIQUE is a cost-effective treatment for ACS patients compared to generic and/or branded clopidogrel. |
| 2011-10-04 | AstraZeneca | Regulatory BRILIQUE receives a positive preliminary medical benefit assessment for the majority of ACS patients in Germany as part of new AMNOG review process astrazeneca.com ↗
AstraZeneca today announced that the German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality and Efficiency in Healthcare (IQWiG) preliminary assessment report regarding the medical benefit of BRILIQUE (ticagrelor). |
| 2011-07-20 | AstraZeneca | Regulatory FDA approves new medicine BRILINTA (ticagrelor) for use in the US astrazeneca.com ↗ |
| 2011-06-01 | AstraZeneca | Regulatory Health Canada approves BRILINTA (ticagrelor tablets) astrazeneca.com ↗
Wednesday, 1 June 2011 AstraZeneca today announced that Health Canada has approved BRILINTA (ticagrelor tablets) for the secondary prevention of atherothrombotic events in patients with Acute Coronary Syndromes (ACS). |
| 2011-05-09 | AstraZeneca | Results Health economics substudy of PLATO shows BRILIQUE to be a cost effective treatment versus generic Clopidogrel astrazeneca.com ↗
AstraZeneca today announced new health economics data from a substudy of the PLATO trial showed that treating a broad spectrum of acute coronary syndrome (ACS) patients with BRILIQUE (ticagrelor) was more cost-effective than treatment with generic clopidogrel. |
| 2011-02-04 | AstraZeneca | Regulatory US FDA assigns new PDUFA date for BRILINTA (ticagrelor tablets) astrazeneca.com ↗
Accordingly, the agency has accepted AstraZeneca’s resubmission of the ticagrelor NDA, categorised it as a Class 2 resubmission to the CRL, and set a new PDUFA date of 20 July 2011. |
| 2011-01-21 | AstraZeneca | Regulatory AstraZeneca Replies To The US FDA Complete Response Letter For BRILINTA (Ticagrelor Tablets) astrazeneca.com ↗
AstraZeneca announced today it has replied to the US Food and Drug Administration’s (FDA) Complete Response Letter (CRL) received for the ticagrelor (BRILINTA) New Drug Application (NDA) on 16 December 2010. |
| 2010-12-17 | AstraZeneca | Regulatory AstraZeneca receives complete response letter from US FDA for BRILINTA (ticagrelor tablets) astrazeneca.com ↗
Friday, 17 December 2010 AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA). |
| 2010-12-06 | AstraZeneca | Regulatory European Commission Approves Brilique™ (Ticagrelor Tablets) astrazeneca.com ↗
AstraZeneca announced today that the European Commission has granted marketing authorisation to BRILIQUE™ (ticagrelor tablets) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (ACS). |
| 2010-09-24 | AstraZeneca | Regulatory BRILIQUE (ticagrelor) receives positive opinion from European CHMP for the treatment of Acute Coronary Syndromes astrazeneca.com ↗
AstraZeneca announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the marketing authorisation application for BRILIQUE™ (ticagrelor) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (ACS). |
| 2010-09-15 | AstraZeneca | Regulatory US Food and Drug Administration Extends Review Timeline For BRILINTA (Ticagrelor) New Drug Application astrazeneca.com ↗
AstraZeneca today announced that the US Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for ticagrelor (BRILINTA). |
| 2010-08-29 | AstraZeneca | Results Genetic substudy shows fewer major cardiovascular events with ticagrelor (brilinta) regardless of relevant genetic variability in ACS patients astrazeneca.com ↗
Regardless of the CYP2C19 genotype, the primary outcome occurred less often with ticagrelor versus clopidogrel (interaction p=0.46). |
| 2010-07-29 | AstraZeneca | Regulatory FDA Advisory Committee recommends US FDA approval of Brilinta (ticagrelor) for Acute Coronary Syndromes astrazeneca.com ↗
AstraZeneca today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca’s investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS). |
| 2010-03-16 | AstraZeneca | Results New PLATO Sub-Analysis of CABG Patients Presented at ACC astrazeneca.com ↗
The patients randomised to ticagrelor had a significantly lower rate of total and CV death than those randomised to clopidogrel treatment: |
| 2009-11-19 | AstraZeneca | Regulatory AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor), an Investigational Antiplatelet Agent astrazeneca.com ↗
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). |
| 2009-11-18 | AstraZeneca | Results Results from Two Phase II Trials Add to Understanding of Brilinta (Ticagrelor) and How it Works in the Body astrazeneca.com ↗
AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL, with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation. |
| 2009-11-16 | AstraZeneca | Results BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI) astrazeneca.com ↗
There was an 18% relative reduction in all cause mortality at one year from 6.0 to 4.9% (P=0.04) with ticagrelor over clopidogrel. |
| 2009-09-25 | AstraZeneca | Results Brilinta Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial astrazeneca.com ↗
Additional findings from this PLATO invasive sub-analysis showed that treatment with BRILINTA, compared to clopidogrel, demonstrated an effect consistent with the results for the entire PLATO population across the multiple secondary efficacy endpoints. |
| 2009-08-30 | AstraZeneca | Results Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients astrazeneca.com ↗
Ticagrelor is the first investigational antiplatelet that has demonstrated a reduction in CV death versus clopidogrel in patients with acute coronary syndromes (ACS). |
| 2009-05-11 | AstraZeneca | Results AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA astrazeneca.com ↗
In PLATO, the overall safety profile for BRILINTA was in line with the safety data observed in the phase II studies. |
All press releases naming this drug 55 releases
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 446 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ticagrelor | “patients aged 18 years or older with an acute coronary syndrome who completed the IVUS-ACS study and who had no major ischaemic or bleeding events after 1-month treatment with...” PMID 38599220 ↗ Apr 2024433“Randomization will be stratified by stent type (cobalt-chromium everolimus-eluting stents, platinum-chromium everolimus-eluting stents, and sirolimus-eluting stents with...” PMID 29447787 ↗ Dec 2017 “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Participants were randomly assigned (1:1) to receive DAPT (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily) for 12 months or the same dual antiplatelet regimen for...” PMID 42120081 ↗ May 2026 “De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg...” NCT04755387 ↗ “The study will be sufficiently powered to provide data primarily regarding the safety of dual therapy with rivaroxaban and ticagrelor over the traditional triple therapy in...” PMID 26003433 ↗ May 2015 “* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce...” NCT01589978 ↗ “Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT04948749 ↗ “Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and...” NCT05955365 ↗ “Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT05980195 ↗ “Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months...” NCT02303717 ↗ |
| Known as | AR-C126532XX | ChEMBL registry synonym — accepted as the source's own label CHEMBL398435 ↗ |
| Known as | AZD6140 | “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗7“Ticagrelor (AZD6140) is a reversible, potent, oral adenosine diphosphate (ADP) P2Y12 receptor blocker” NCT03881943 ↗ |
| Known as | Brilavus | “the other one took ASA 80 mg once a day and ticagrelor 90 mg that is produced by Abidi company available in market as Brilavus twice a day” NCT05858918 ↗ |
| Known as | BRILINTA | “Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks” NCT02459288 ↗5“Ticagrelor (Brilinta®) (AstraZeneca Pharmaceuticals, Wilmington, NC, USA).” PMID 23826440 ↗ Jun 2013 “Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed” NCT04567290 ↗ “A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3:” NCT07444164 ↗ “Ticagrelor Oral Tablet [Brilinta]” NCT04946929 ↗ |
| Known as | BRILINTA (ticagrelor) | “"Brilinta"(Ticagrelor)” NCT02064985 ↗3“BRILINTA (ticagrelor)” NCT01589978 ↗ “Brilinta (ticagrelor)” NCT01823510 ↗ “Brilinta (ticagrelor” NCT01642238 ↗ |
| Known as | Brilique | “It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets...” NCT02251249 ↗3“Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.” NCT04688723 ↗ “Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water” NCT02400333 ↗ “Drug: Ticagrelor (Brilique) 90” NCT03884530 ↗ |
| Known as | Possia | ChEMBL registry synonym — accepted as the source's own label CHEMBL398435 ↗ |
| Known as | Ticag. | “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗ |
| Known as | Ticagrelor (Brilinta) | “Ticagrelor (Brilinta)” NCT02406911 ↗ |
| Known as | Ticagrelor (Brilique) | “Ticagrelor (Brilique)” NCT02224274 ↗ |
| Action | Inhibit | “Ticagrelor is an oral, reversible, direct-acting inhibitor” PMID 19717846 ↗ Aug 2009 |
| Modality | Small molecule | “cyclopentyl-triazolo-pyrimidine ticagrelor” PMID 24371012 ↗ Dec 2013 |
| Route | Oral | “Ticagrelor is an oral, reversible, direct-acting inhibitor” PMID 19717846 ↗ Aug 2009 |
| Target | P2RY12 | “ticagrelor, a reversibly binding P2Y(12) receptor antagonist” PMID 24861133 ↗ Aug 2014 |